- Precision BioSciences Inc DTIL announced additional data from its Phase 1/2a study evaluating PBCAR0191, off-the-shelf, allogeneic CAR T candidate targeting CD19.
- Data will be presented at the 2021 American Society of Clinical Oncology Meeting.
- As of February, 13 subjects with CD19+ relapsed/refractory Non-Hodgkin lymphoma were evaluable.
- The overall response rate was 77% (10/13 patients).
- Peak PBCAR0191 expansion was increased 56-fold and was associated with a CR rate of 71% in the enhanced lymphodepleted group versus 33% in the standard lymphodepleted group.
- Duration of response assessment is ongoing.
- To date, most adverse events reported were mild, with no cases of graft versus host disease or severe cytokine release syndrome.
- Price Action: DTIL shares are 7.26% at $10.05 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
